000 03497 am a22006733u 4500
042 _adc
100 1 0 _aGur, Chamutal
_eauthor
_91055
700 1 0 _aWang, Shuang-Yin
_eauthor
_91056
700 1 0 _aSheban, Fadi
_eauthor
_91057
700 1 0 _aZada, Mor
_eauthor
_91058
700 1 0 _aLi, Baoguo
_eauthor
_91059
700 1 0 _aKharouf, Fadi
_eauthor
_91060
700 1 0 _aPeleg, Hagit
_eauthor
_91061
700 1 0 _aAamar, Suhail
_eauthor
_91062
700 1 0 _aYalin, Adam
_eauthor
_91063
700 1 0 _aKirschenbaum, Daniel
_eauthor
_91064
700 1 0 _aBraun-Moscovici, Yolanda
_eauthor
_91065
700 1 0 _aJaitin, Diego Adhemar
_eauthor
_91066
700 1 0 _ameir-salame, Tomer
_eauthor
_91067
700 1 0 _aHagai, Efrat
_eauthor
_91068
700 1 0 _aKragesteen, Bjørt K.
_eauthor
_91069
700 1 0 _aAvni, Batia
_eauthor
_91070
700 1 0 _aGrisariu, Sigal
_eauthor
_91071
700 1 0 _aBornstein, Chamutal
_eauthor
_91072
700 1 0 _aShlomi-Loubaton, Shir
_eauthor
_91073
700 1 0 _aDavid, Eyal
_eauthor
_91074
700 1 0 _aShreberk-Hassidim, Rony
_eauthor
_91075
700 1 0 _aMolho-Pessach, Vered
_eauthor
_91076
700 1 0 _aAmar, Dalit
_eauthor
_91077
700 1 0 _aTzur, Tomer
_eauthor
_91078
700 1 0 _aKuint, Rottem
_eauthor
_91079
700 1 0 _aGross, Moshe
_eauthor
_91080
700 1 0 _aBarboy, Oren
_eauthor
_91081
700 1 0 _aMoshe, Adi
_eauthor
_91082
700 1 0 _aFellus-Alyagor, Liat
_eauthor
_91083
700 1 0 _aHirsch, Dana
_eauthor
_91084
700 1 0 _aAddadi, Yoseph
_eauthor
_91085
700 1 0 _aErenfeld, Shlomit
_eauthor
_91086
700 1 0 _aBiton, Moshe
_eauthor
_91087
700 1 0 _aTzemach, Tehila
_eauthor
_91088
700 1 0 _aElazary, Anat
_eauthor
_91089
700 1 0 _aNaparstek, Yaakov
_eauthor
_91090
700 1 0 _aTzemach, Reut
_eauthor
_91091
700 1 0 _aWeiner, Assaf
_eauthor
_91092
700 1 0 _aGiladi, Amir
_eauthor
_91093
700 1 0 _aBalbir-Gurman, Alexandra
_eauthor
_91094
700 1 0 _aAmit, Ido
_eauthor
_91095
245 0 0 _aLGR5 expressing skin fibroblasts define a major cellular hub perturbed in scleroderma
260 _c2022-04-14.
500 _a/pmc/articles/PMC7612792/
500 _a/pubmed/35381199
520 _aSystemic sclerosis (scleroderma, SSc) is an incurable autoimmune disease with high morbidity and mortality rates. Here, we conducted a population-scale single-cell genomic analysis of skin and blood samples of 56 healthy controls and 97 SSc patients at different stages of the disease. We found immune compartment dysfunction only in a specific subtype of diffuse SSc patients but global dysregulation of the stromal compartment, particularly in a previously undefined subset of LGR5(+)-scleroderma-associated fibroblasts (ScAFs). ScAFs are perturbed morphologically and molecularly in SSc patients. Single-cell multiome profiling of stromal cells revealed ScAF-specific markers, pathways, regulatory elements, and transcription factors underlining disease development. Systematic analysis of these molecular features with clinical metadata associates specific ScAF targets with disease pathogenesis and SSc clinical traits. Our high-resolution atlas of the sclerodermatous skin spectrum will enable a paradigm shift in the understanding of SSc disease and facilitate the development of biomarkers and therapeutic strategies.
540 _a
546 _aen
690 _aArticle
655 7 _aText
_2local
786 0 _nCell
856 4 1 _uhttp://dx.doi.org/10.1016/j.cell.2022.03.011
_zConnect to this object online.
999 _c1830
_d1830